Sandler Howard M, Narayan Samir, Smith David C
Department of Radiation Oncology, University of Michigan Medical School, 1500 E. Medical Center Drive, UH B2C490, Ann Arbor, MI 48109-0010, USA.
Semin Oncol. 2003 Aug;30(4 Suppl 9):95-100. doi: 10.1016/s0093-7754(03)00274-4.
Chemotherapy for prostate cancer currently has an established role in the treatment of hormone-refractory prostate cancer. There is strong evidence that combined modality treatment with androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosis, perhaps because of an effect of androgen ablation on subclinical distant disease. There are currently several clinical trials investigating whether the addition of chemotherapy with known efficacy in the hormone-refractory setting can provide a survival advantage when used adjuvantly. The role of chemotherapy for patients with nonmetastatic, hormone-naive prostate cancer will be discussed.
目前，化疗在激素难治性前列腺癌的治疗中已确立了其作用。有强有力的证据表明，对于预后较差的患者，除放疗外联合雄激素去除疗法进行综合治疗比单纯放疗更有益处，这可能是因为雄激素去除疗法对亚临床远处疾病有作用。目前有几项临床试验正在研究，在激素难治性情况下已知有效的化疗药物辅助使用时能否带来生存优势。本文将讨论化疗在非转移性、激素初治前列腺癌患者中的作用。
